Key result
Levosimendan was successfully and safely used in 2 critically ill term newborns with acute heart failure and pulmonary hypertension.
Why the study?
Does levosimendan improve outcomes in critically ill term newborns with acute heart failure and pulmonary hypertension?
Case Report (n=2)
Does levosimendan improve outcomes in critically ill term newborns with acute heart failure and pulmonary hypertension?
Levosimendan may be a safe and effective treatment option for acute heart failure and pulmonary hypertension in term neonates without structural heart disease.
Answers are grounded in this paper and cite their sources.
Should not yet change practice; hypothesis-generating for levosimendan in term neonates with acute heart failure and pulmonary hypertension.
We report the successful and safe use of levosimendan, a new calcium-sensitizing agent with positive inotropic and vasodilatory action, in 2 critically ill term newborns with acute heart failure and pulmonary hypertension in the absence of any underlying heart malformation and/or previous cardiosurgical procedures. During the neonatal period, levosimendan may represent an ideal drug for immature myocardium characterized by a higher calcium-dependent contractility than in adults.
No takes yet. Share an insight, caveat, or question.
Carolis et al. (2011) conducted a case report in Acute heart failure and pulmonary hypertension (n=2). Levosimendan was evaluated on Successful and safe use. Levosimendan was successfully and safely used in 2 critically ill term newborns with acute heart failure and pulmonary hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: